Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

Regorafenib, a novel multikinase inhibitor, has recently demonstrated overall survival benefits in metastatic colorectal cancer (CRC) patients. Our study aimed to gain further insight into the molecular mechanisms of regorafenib and to assess its potential in combination therapy. Regorafenib was tes...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Int J Cancer
Главные авторы: Schmieder, Roberta, Hoffmann, Jens, Becker, Michael, Bhargava, Ajay, Müller, Tina, Kahmann, Nicole, Ellinghaus, Peter, Adams, Robert, Rosenthal, André, Thierauch, Karl-Heinz, Scholz, Arne, Wilhelm, Scott M, Zopf, Dieter
Формат: Artigo
Язык:Inglês
Опубликовано: BlackWell Publishing Ltd 2014
Предметы:
Cancer Therapy
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4277327/
https://ncbi.nlm.nih.gov/pubmed/24347491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.28669
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы